Immunotherapy company CuraCell has dosed the first patients with its treatment for metastatic colorectal and metastatic prostate cancer. 

CC-38 is novel autologous Tumour-Infiltrating Lymphocyte (TIL) therapy, currently being evaluated in Phase I/IIa trial. Up to 16 patients with Stage IV colorectal and prostate cancer will be enrolled in the trial, which will assess the safety and tolerability of CC-38. 

Secondary endpoints of the trial include preliminary efficacy, immune profiling, and feasibility of repeated administration. 

The treatment was developed using CuraCell’s proprietary TIL therapy, which itself was produced using the company’s CytoPLY platform. CytoPLY enhances the activation and enrichment of tumour-reactive lymphocytes, aiming to generate potent and diverse anti-tumour immune responses.  

“Including the first patient is a pivotal step in translating CuraCell’s TIL platform from scientific innovation to clinical impact,” said Torbjörn Ström, Clinical Operations Manager at CuraCell.  

“We are pleased to see the trial now actively enrolling and look forward to working closely with our clinical partners to deliver high-quality execution and meaningful outcomes for patients.”